Manufacturing

Articles

AzarGen’s biosimilar, made in iBio’s plant-based system, will be compared to the original molecule in pre-clinical studies.

iBio Supports AzarGen Biotechnologies’ Development of a Rituximab Biosimilar

The partnership will provide cost effective biologics for the world market.

Celltrion and Lonza Sign Contract to Manufacture Remsima Drug Substance

A global agreement with Polpharma Biologics gives Sandoz commercialization rights to a proposed biosimilar natalizumab for relapsing-remitting multiple sclerosis.

Sandoz in Deal to Commercialize Biosimilar Natalizumab

This article provides a review of various 2000-L single-use bioreactors used by biopharmaceutical suppliers for commercial production.

Single-Use Bioreactors Unwrap Commercial Manufacturing Options

Pharmaceutical Technology and BioPharm International will present a Keynote Session on Meeting Bioprocessing Manufacturing Capacity Demands on Wednesday, April 3, 2019, during INTERPHEX 2019 at the Javits Center in New York City.

Biologic Drug Manufacturing Capacity on the Agenda for INTERPHEX 2019 Keynote Series

Editor of Pharmaceutical Technology Europe

To achieve further cost reductions in biosimilar manufacturing, a move away from traditional models is necessary.


Reinventing the Biomanufacturing Wheel

The company is set to expand biologics and fill/finish capacity at its biologics manufacturing sites in Madison, WI, and Bloomington, IN.

Catalent Invests $200 Million in Wisconsin and Indiana Sites

Anurag S. Rathore is a professor in the Department of Chemical Engineering at the Indian Institute of Technology Delhi and a member of BioPharm International's Editorial Advisory Board, Tel. +91.9650770650, asrathore@biotechcmz.com.

Rohit Bansal is PhD Research Scholar in the Department of Chemical Engineering at the Indian Institute of Technology (Delhi).

Kinetic models can be used to study aggregation and fragmentation to help ensure stability.

Modeling the Degradation of mAb Therapeutics

Experts believe that the contract development and manufacturing organization market will reach $17.38 billion by 2022, with disruptive business models using Industrial Internet of Things (IIot) and single-use technologies proving more profitable and efficient in the long term.

Single-use and IIoT Solutions Expected to Reduce Costs and Enhance Production Efficiency

The maturation of single-use technologies presents commercial bioprocessing options for small-volume drug products.  

Manufacturing, Biosimilars and Biobetters